Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Cancer cells often evade immune detection by upregulating PD-L1.
• Chemotherapy and immunotherapy can be limited by drug resistance and systemic toxicity.
• Targeted delivery systems are needed to enhance therapeutic efficacy and reduce side effects.

Purpose of the Study:

• To develop dual drug-loaded nanoparticles (DOX/miR-NPs) for co-delivery of doxorubicin (DOX) and miR-200c.
• To inhibit programmed death-1 receptor (PD-L1) expression and induce immunogenic cell death (ICD).
• To evaluate the efficacy of folate-targeted nanoparticles in a tumor microenvironment.

Main Methods:

• Formulation of dual drug-loaded nanoparticles using folic acid (FA)-conjugated PLGA-PEG and PLGA-PEI block copolymers.
• Characterization of nanoparticle size, distribution, and stability.
• In vitro and in vivo evaluation of nanoparticle uptake, PD-L1 inhibition, ICD induction, and anti-tumor effects.

Main Results:

• FA-modified nanoparticles showed enhanced cancer cell uptake and tumor accumulation.
• DOX/miR-NPs effectively inhibited PD-L1 expression and induced ICD in cancer cells.
• Folate-targeted nanoparticles significantly inhibited tumor growth compared to free drugs or single-drug nanoparticles.

Conclusions:

• Simultaneous PD-L1 inhibition and ICD induction via co-delivery nanoparticles represent a promising strategy for cancer therapy.
• Low-dose doxorubicin combined with miR-200c in targeted nanoparticles enhances anti-tumor immunity.
• This approach offers a potential improvement over conventional cancer treatment methods.